Tags Archive Navigation
icon
-
Media ReleaseNovartis Cosentyx® gains fourth indication in EU with first-in-class approval in axial spondyloarthritis spectrum
-
Media ReleaseNovartis study reveals that migraine support in the workspace can significantly decrease the impact of the disease on affected employees
-
Media ReleaseNovartis announces new late-breaking ofatumumab data at EAN demonstrating robust efficacy and safety in the treatment of relapsing forms of multiple sclerosis (RMS)
-
Media ReleaseNovartis data highlight benefit of early treatment initiation in patients with secondary progressive multiple sclerosis (SPMS)
-
Media ReleaseNovartis PREVENT data show Cosentyx® helps patients realize early and lasting relief in axial spondyloarthritis
-
Media ReleaseNovartis Phase IIIb ARGON study meets primary endpoint in a comparison of Enerzair® Breezhaler® (QVM149) versus a free combination of two existing inhaled treatments in uncontrolled asthma
-
Media ReleaseNovartis receives positive CHMP opinion for new Xolair® indication to treat severe chronic rhinosinusitis with nasal polyps
-
Media ReleaseNovartis Cosentyx® gains positive CHMP opinion for pediatric psoriasis, reinforcing established efficacy and safety profile
-
Media ReleaseNovartis receives EC approval for Enerzair® Breezhaler®, including the first digital companion (sensor and app) that can be prescribed alongside a treatment for uncontrolled asthma in the EU
-
Media ReleaseNovartis Phase III IRIDIUM data in Lancet Respiratory Medicine show benefit of Enerzair® Breezhaler® (QVM149), the first-in-class inhaled LABA/LAMA/ICS combination in uncontrolled asthma
-
Media ReleaseNovartis Cosentyx® receives EU approval for first-line systemic treatment in pediatric psoriasis
-
Media ReleaseNovartis announces NEJM publication of Phase III ASCLEPIOS trials demonstrating superior efficacy of ofatumumab in patients with relapsing multiple sclerosis
Pagination
- ‹ Previous page
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- › Next page